Home 5 Articles 5 Biopharma M&A Expected to Rebound After Sluggish 2021

Biopharma M&A Expected to Rebound After Sluggish 2021

by | Mar 1, 2022

Most of the big M&A deals in the diagnostics space that came down in 2021 involved medtech and life sciences companies. The biopharma sector was conspicuously quiet during all of this activity. But analysts expect that to change soon. Why 2022 Could Be a Big Year for Biopharma M&A  Biopharma companies are big and have […]

Most of the big M&A deals in the diagnostics space that came down in 2021 involved medtech and life sciences companies. The biopharma sector was conspicuously quiet during all of this activity. But analysts expect that to change soon. Why 2022 Could Be a Big Year for Biopharma M&A  Biopharma companies are big and have […]

This content is Exclusive to Lab Industry Report Subscribers

Subscribe or Log in for Exclusive Access.